Precision Medicine in Hereditary Cancer and Sarcoma; targeted surveillance, immunotherapy and individualized follow-up

Project: Research

Description

This project is based on epidemiologic approaches, genomic profiling and immunogenic expression analyses aimed to refine diagnostics, individualize surveillance and develop precision medicine for hereditary colorectal cancer and soft tissue sarcoma. These rare tumor types are interconnected through hypermutability/genetic complexity and immunotherapy-based treatment possibilities. The projects are coordinated by the main applicant (Mef Nilbert) and are built on collaborative efforts within a multiprofessional environment hosting epidemiologists, basic scientists, bioinformaticians, biostatisticians, pathologists, surgeons, oncologists and researchers in training.

SPECIFIC AIMS

The aims of the three substudies relate to:

1. Risk modelling for individualized surveillance and follow-up in
- the hereditary colorectal cancer subsets Lynch syndrome, familial colorectal cancer type X and late onset colorectal cancer through analyses of the risk of extracolonic cancers, interval cancers and metachronous cancers and determination of causes of death
- radiation-induced sarcoma

2. Molecular taxonomy studies of
- extracolonic cancers in Lynch syndrome
- radiation-induced angiosarcoma

3. Prediction of benefit from immunotherapy through
- delineation of an immune-response signature in mismatch-repair deficient colorectal cancers linked to Lynch syndrome
- evaluation of PD-L1 expression in sarcoma for prediction of response and resistance to PD-1 inhibitory treatment of advanced disease


Layman's description

This project is based on epidemiologic approaches, genomic profiling and immunogenic expression analyses aimed to refine diagnostics, individualize surveillance and develop precision medicine for hereditary colorectal cancer and soft tissue sarcoma. These rare tumor types are interconnected through hypermutability/genetic complexity and immunotherapy-based treatment possibilities. The projects are coordinated by the main applicant (Mef Nilbert) and are built on collaborative efforts within a multiprofessional environment hosting epidemiologists, basic scientists, bioinformaticians, biostatisticians, pathologists, surgeons, oncologists and researchers in training.
Short titlePrecision Medicine in Hereditary Cancer and Sarcoma
StatusNot started

Participants

Related research output

Anna Rohlin, Eva Rambech, Anders Kvist, Therese Törngren, Frida Eiengård, Ulf Lundstam, Theofanis Zagoras, Samuel Gebre-Medhin, Åke Borg, Jan Björk, Mef Nilbert & Margareta Nordling, 2017 Apr, In: Familial Cancer. 16, 2, p. 195-203

Research output: Contribution to journalArticle

Kristina Lagerstedt-Robinson, Anna Rohlin, Christos Aravidis, Beatrice Melin, Margareta Nordling, Marie Stenmark-Askmalm, Annika Lindblom & Mef Nilbert, 2016 Nov 1, In: Oncology Reports. 36, 5, p. 2823-2835 13 p.

Research output: Contribution to journalArticle

Fredrik Liedberg, Ulf Gerdtham, Katarina Gralén, Sigurdur Gudjonsson, Staffan Jahnson, Irene Johansson, Oskar Hagberg, Staffan Larsson, Anna Karin Lind, Annika Löfgren, Jenny Wanegård, Hanna Åberg & Mef Nilbert, 2016, In: British Journal of Cancer. 115, p. 770-775 6 p.

Research output: Contribution to journalArticle

View all (14)